カテゴリ： 世界, 医療/バイオ, Market Monitor Global

抗CD31抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル

■ 英語タイトル：Anti-CD31 Antibody Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23DC12248）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23DC12248
■ 発行日：2023年12月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医療
■ ページ数：113
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[抗CD31抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の抗CD31抗体市場規模と予測を収録しています。・世界の抗CD31抗体市場：売上、2018年-2023年、2024年-2029年
・世界の抗CD31抗体市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の抗CD31抗体市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「モノクローナル」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

抗CD31抗体のグローバル主要企業は、BosterBio、 Bio-Rad、 BD Biosciences、 Abcam、 RayBiotech、 GeneTex、 BioLegend、 BMA Biomedicals、 Bethyl Laboratories、 SouthernBiotech、 Elabscience Biotechnology Inc、 Merck、 Leica Biosystems、 Beijing Solarbio Science & Technology、 Wuhan Fine Biotechなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、抗CD31抗体のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の抗CD31抗体市場：タイプ別、2018年-2023年、2024年-2029年
世界の抗CD31抗体市場：タイプ別市場シェア、2022年
・モノクローナル、ポリクローナル

世界の抗CD31抗体市場：用途別、2018年-2023年、2024年-2029年
世界の抗CD31抗体市場：用途別市場シェア、2022年
・免疫化学、免疫蛍光、免疫沈降、ウェスタンブロット、その他

世界の抗CD31抗体市場：地域・国別、2018年-2023年、2024年-2029年
世界の抗CD31抗体市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における抗CD31抗体のグローバル売上、2018年-2023年
・主要企業における抗CD31抗体のグローバル売上シェア、2022年
・主要企業における抗CD31抗体のグローバル販売量、2018年-2023年
・主要企業における抗CD31抗体のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
BosterBio、 Bio-Rad、 BD Biosciences、 Abcam、 RayBiotech、 GeneTex、 BioLegend、 BMA Biomedicals、 Bethyl Laboratories、 SouthernBiotech、 Elabscience Biotechnology Inc、 Merck、 Leica Biosystems、 Beijing Solarbio Science & Technology、 Wuhan Fine Biotech

*************************************************************

・調査・分析レポートの概要
抗CD31抗体市場の定義
市場セグメント
世界の抗CD31抗体市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の抗CD31抗体市場規模
世界の抗CD31抗体市場規模：2022年 VS 2029年
世界の抗CD31抗体市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの抗CD31抗体の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の抗CD31抗体製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：モノクローナル、ポリクローナル
抗CD31抗体のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：免疫化学、免疫蛍光、免疫沈降、ウェスタンブロット、その他
抗CD31抗体の用途別グローバル売上・予測

・地域別市場分析
地域別抗CD31抗体市場規模 2022年と2029年
地域別抗CD31抗体売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
BosterBio、 Bio-Rad、 BD Biosciences、 Abcam、 RayBiotech、 GeneTex、 BioLegend、 BMA Biomedicals、 Bethyl Laboratories、 SouthernBiotech、 Elabscience Biotechnology Inc、 Merck、 Leica Biosystems、 Beijing Solarbio Science & Technology、 Wuhan Fine Biotech
...

This research report provides a comprehensive analysis of the Anti-CD31 Antibody market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Anti-CD31 Antibody market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Anti-CD31 Antibody, challenges faced by the industry, and potential opportunities for market players.
The global Anti-CD31 Antibody market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Anti-CD31 Antibody market presents opportunities for various stakeholders, including Immunochemistry, Immunofluorescence. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Anti-CD31 Antibody market. Additionally, the growing consumer demand present avenues for market expansion.
The global Anti-CD31 Antibody market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Anti-CD31 Antibody market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Anti-CD31 Antibody market.
Market Overview: The report provides a comprehensive overview of the Anti-CD31 Antibody market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Monoclonal, Polyclonal), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Anti-CD31 Antibody market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Anti-CD31 Antibody market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Anti-CD31 Antibody market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Anti-CD31 Antibody market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Anti-CD31 Antibody market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Anti-CD31 Antibody market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Anti-CD31 Antibody, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Anti-CD31 Antibody market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Anti-CD31 Antibody market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Monoclonal
Polyclonal
Market segment by Application
Immunochemistry
Immunofluorescence
Immunoprecipitation
Western Blot
Others
Global Anti-CD31 Antibody Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
BosterBio
Bio-Rad
BD Biosciences
Abcam
RayBiotech
GeneTex
BioLegend
BMA Biomedicals
Bethyl Laboratories
SouthernBiotech
Elabscience Biotechnology Inc
Merck
Leica Biosystems
Beijing Solarbio Science & Technology
Wuhan Fine Biotech
Outline of Major Chapters:
Chapter 1: Introduces the definition of Anti-CD31 Antibody, market overview.
Chapter 2: Global Anti-CD31 Antibody market size in revenue and volume.
Chapter 3: Detailed analysis of Anti-CD31 Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-CD31 Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Anti-CD31 Antibody capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Anti-CD31 Antibody Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Anti-CD31 Antibody Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Anti-CD31 Antibody Overall Market Size
2.1 Global Anti-CD31 Antibody Market Size: 2022 VS 2029
2.2 Global Anti-CD31 Antibody Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Anti-CD31 Antibody Sales: 2018-2029
3 Company Landscape
3.1 Top Anti-CD31 Antibody Players in Global Market
3.2 Top Global Anti-CD31 Antibody Companies Ranked by Revenue
3.3 Global Anti-CD31 Antibody Revenue by Companies
3.4 Global Anti-CD31 Antibody Sales by Companies
3.5 Global Anti-CD31 Antibody Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Anti-CD31 Antibody Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Anti-CD31 Antibody Product Type
3.8 Tier 1, Tier 2 and Tier 3 Anti-CD31 Antibody Players in Global Market
3.8.1 List of Global Tier 1 Anti-CD31 Antibody Companies
3.8.2 List of Global Tier 2 and Tier 3 Anti-CD31 Antibody Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Anti-CD31 Antibody Market Size Markets, 2022 & 2029
4.1.2 Monoclonal
4.1.3 Polyclonal
4.2 By Type – Global Anti-CD31 Antibody Revenue & Forecasts
4.2.1 By Type – Global Anti-CD31 Antibody Revenue, 2018-2023
4.2.2 By Type – Global Anti-CD31 Antibody Revenue, 2024-2029
4.2.3 By Type – Global Anti-CD31 Antibody Revenue Market Share, 2018-2029
4.3 By Type – Global Anti-CD31 Antibody Sales & Forecasts
4.3.1 By Type – Global Anti-CD31 Antibody Sales, 2018-2023
4.3.2 By Type – Global Anti-CD31 Antibody Sales, 2024-2029
4.3.3 By Type – Global Anti-CD31 Antibody Sales Market Share, 2018-2029
4.4 By Type – Global Anti-CD31 Antibody Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Anti-CD31 Antibody Market Size, 2022 & 2029
5.1.2 Immunochemistry
5.1.3 Immunofluorescence
5.1.4 Immunoprecipitation
5.1.5 Western Blot
5.1.6 Others
5.2 By Application – Global Anti-CD31 Antibody Revenue & Forecasts
5.2.1 By Application – Global Anti-CD31 Antibody Revenue, 2018-2023
5.2.2 By Application – Global Anti-CD31 Antibody Revenue, 2024-2029
5.2.3 By Application – Global Anti-CD31 Antibody Revenue Market Share, 2018-2029
5.3 By Application – Global Anti-CD31 Antibody Sales & Forecasts
5.3.1 By Application – Global Anti-CD31 Antibody Sales, 2018-2023
5.3.2 By Application – Global Anti-CD31 Antibody Sales, 2024-2029
5.3.3 By Application – Global Anti-CD31 Antibody Sales Market Share, 2018-2029
5.4 By Application – Global Anti-CD31 Antibody Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Anti-CD31 Antibody Market Size, 2022 & 2029
6.2 By Region – Global Anti-CD31 Antibody Revenue & Forecasts
6.2.1 By Region – Global Anti-CD31 Antibody Revenue, 2018-2023
6.2.2 By Region – Global Anti-CD31 Antibody Revenue, 2024-2029
6.2.3 By Region – Global Anti-CD31 Antibody Revenue Market Share, 2018-2029
6.3 By Region – Global Anti-CD31 Antibody Sales & Forecasts
6.3.1 By Region – Global Anti-CD31 Antibody Sales, 2018-2023
6.3.2 By Region – Global Anti-CD31 Antibody Sales, 2024-2029
6.3.3 By Region – Global Anti-CD31 Antibody Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Anti-CD31 Antibody Revenue, 2018-2029
6.4.2 By Country – North America Anti-CD31 Antibody Sales, 2018-2029
6.4.3 US Anti-CD31 Antibody Market Size, 2018-2029
6.4.4 Canada Anti-CD31 Antibody Market Size, 2018-2029
6.4.5 Mexico Anti-CD31 Antibody Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Anti-CD31 Antibody Revenue, 2018-2029
6.5.2 By Country – Europe Anti-CD31 Antibody Sales, 2018-2029
6.5.3 Germany Anti-CD31 Antibody Market Size, 2018-2029
6.5.4 France Anti-CD31 Antibody Market Size, 2018-2029
6.5.5 U.K. Anti-CD31 Antibody Market Size, 2018-2029
6.5.6 Italy Anti-CD31 Antibody Market Size, 2018-2029
6.5.7 Russia Anti-CD31 Antibody Market Size, 2018-2029
6.5.8 Nordic Countries Anti-CD31 Antibody Market Size, 2018-2029
6.5.9 Benelux Anti-CD31 Antibody Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Anti-CD31 Antibody Revenue, 2018-2029
6.6.2 By Region – Asia Anti-CD31 Antibody Sales, 2018-2029
6.6.3 China Anti-CD31 Antibody Market Size, 2018-2029
6.6.4 Japan Anti-CD31 Antibody Market Size, 2018-2029
6.6.5 South Korea Anti-CD31 Antibody Market Size, 2018-2029
6.6.6 Southeast Asia Anti-CD31 Antibody Market Size, 2018-2029
6.6.7 India Anti-CD31 Antibody Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Anti-CD31 Antibody Revenue, 2018-2029
6.7.2 By Country – South America Anti-CD31 Antibody Sales, 2018-2029
6.7.3 Brazil Anti-CD31 Antibody Market Size, 2018-2029
6.7.4 Argentina Anti-CD31 Antibody Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Anti-CD31 Antibody Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Anti-CD31 Antibody Sales, 2018-2029
6.8.3 Turkey Anti-CD31 Antibody Market Size, 2018-2029
6.8.4 Israel Anti-CD31 Antibody Market Size, 2018-2029
6.8.5 Saudi Arabia Anti-CD31 Antibody Market Size, 2018-2029
6.8.6 UAE Anti-CD31 Antibody Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 BosterBio
7.1.1 BosterBio Company Summary
7.1.2 BosterBio Business Overview
7.1.3 BosterBio Anti-CD31 Antibody Major Product Offerings
7.1.4 BosterBio Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.1.5 BosterBio Key News & Latest Developments
7.2 Bio-Rad
7.2.1 Bio-Rad Company Summary
7.2.2 Bio-Rad Business Overview
7.2.3 Bio-Rad Anti-CD31 Antibody Major Product Offerings
7.2.4 Bio-Rad Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.2.5 Bio-Rad Key News & Latest Developments
7.3 BD Biosciences
7.3.1 BD Biosciences Company Summary
7.3.2 BD Biosciences Business Overview
7.3.3 BD Biosciences Anti-CD31 Antibody Major Product Offerings
7.3.4 BD Biosciences Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.3.5 BD Biosciences Key News & Latest Developments
7.4 Abcam
7.4.1 Abcam Company Summary
7.4.2 Abcam Business Overview
7.4.3 Abcam Anti-CD31 Antibody Major Product Offerings
7.4.4 Abcam Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.4.5 Abcam Key News & Latest Developments
7.5 RayBiotech
7.5.1 RayBiotech Company Summary
7.5.2 RayBiotech Business Overview
7.5.3 RayBiotech Anti-CD31 Antibody Major Product Offerings
7.5.4 RayBiotech Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.5.5 RayBiotech Key News & Latest Developments
7.6 GeneTex
7.6.1 GeneTex Company Summary
7.6.2 GeneTex Business Overview
7.6.3 GeneTex Anti-CD31 Antibody Major Product Offerings
7.6.4 GeneTex Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.6.5 GeneTex Key News & Latest Developments
7.7 BioLegend
7.7.1 BioLegend Company Summary
7.7.2 BioLegend Business Overview
7.7.3 BioLegend Anti-CD31 Antibody Major Product Offerings
7.7.4 BioLegend Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.7.5 BioLegend Key News & Latest Developments
7.8 BMA Biomedicals
7.8.1 BMA Biomedicals Company Summary
7.8.2 BMA Biomedicals Business Overview
7.8.3 BMA Biomedicals Anti-CD31 Antibody Major Product Offerings
7.8.4 BMA Biomedicals Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.8.5 BMA Biomedicals Key News & Latest Developments
7.9 Bethyl Laboratories
7.9.1 Bethyl Laboratories Company Summary
7.9.2 Bethyl Laboratories Business Overview
7.9.3 Bethyl Laboratories Anti-CD31 Antibody Major Product Offerings
7.9.4 Bethyl Laboratories Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.9.5 Bethyl Laboratories Key News & Latest Developments
7.10 SouthernBiotech
7.10.1 SouthernBiotech Company Summary
7.10.2 SouthernBiotech Business Overview
7.10.3 SouthernBiotech Anti-CD31 Antibody Major Product Offerings
7.10.4 SouthernBiotech Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.10.5 SouthernBiotech Key News & Latest Developments
7.11 Elabscience Biotechnology Inc
7.11.1 Elabscience Biotechnology Inc Company Summary
7.11.2 Elabscience Biotechnology Inc Business Overview
7.11.3 Elabscience Biotechnology Inc Anti-CD31 Antibody Major Product Offerings
7.11.4 Elabscience Biotechnology Inc Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.11.5 Elabscience Biotechnology Inc Key News & Latest Developments
7.12 Merck
7.12.1 Merck Company Summary
7.12.2 Merck Business Overview
7.12.3 Merck Anti-CD31 Antibody Major Product Offerings
7.12.4 Merck Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.12.5 Merck Key News & Latest Developments
7.13 Leica Biosystems
7.13.1 Leica Biosystems Company Summary
7.13.2 Leica Biosystems Business Overview
7.13.3 Leica Biosystems Anti-CD31 Antibody Major Product Offerings
7.13.4 Leica Biosystems Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.13.5 Leica Biosystems Key News & Latest Developments
7.14 Beijing Solarbio Science & Technology
7.14.1 Beijing Solarbio Science & Technology Company Summary
7.14.2 Beijing Solarbio Science & Technology Business Overview
7.14.3 Beijing Solarbio Science & Technology Anti-CD31 Antibody Major Product Offerings
7.14.4 Beijing Solarbio Science & Technology Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.14.5 Beijing Solarbio Science & Technology Key News & Latest Developments
7.15 Wuhan Fine Biotech
7.15.1 Wuhan Fine Biotech Company Summary
7.15.2 Wuhan Fine Biotech Business Overview
7.15.3 Wuhan Fine Biotech Anti-CD31 Antibody Major Product Offerings
7.15.4 Wuhan Fine Biotech Anti-CD31 Antibody Sales and Revenue in Global (2018-2023)
7.15.5 Wuhan Fine Biotech Key News & Latest Developments
8 Global Anti-CD31 Antibody Production Capacity, Analysis
8.1 Global Anti-CD31 Antibody Production Capacity, 2018-2029
8.2 Anti-CD31 Antibody Production Capacity of Key Manufacturers in Global Market
8.3 Global Anti-CD31 Antibody Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Anti-CD31 Antibody Supply Chain Analysis
10.1 Anti-CD31 Antibody Industry Value Chain
10.2 Anti-CD31 Antibody Upstream Market
10.3 Anti-CD31 Antibody Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Anti-CD31 Antibody Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Anti-CD31 Antibody in Global Market
Table 2. Top Anti-CD31 Antibody Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Anti-CD31 Antibody Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Anti-CD31 Antibody Revenue Share by Companies, 2018-2023
Table 5. Global Anti-CD31 Antibody Sales by Companies, (K Units), 2018-2023
Table 6. Global Anti-CD31 Antibody Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Anti-CD31 Antibody Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Anti-CD31 Antibody Product Type
Table 9. List of Global Tier 1 Anti-CD31 Antibody Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Anti-CD31 Antibody Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Anti-CD31 Antibody Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Anti-CD31 Antibody Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Anti-CD31 Antibody Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Anti-CD31 Antibody Sales (K Units), 2018-2023
Table 15. By Type - Global Anti-CD31 Antibody Sales (K Units), 2024-2029
Table 16. By Application – Global Anti-CD31 Antibody Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Anti-CD31 Antibody Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Anti-CD31 Antibody Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Anti-CD31 Antibody Sales (K Units), 2018-2023
Table 20. By Application - Global Anti-CD31 Antibody Sales (K Units), 2024-2029
Table 21. By Region – Global Anti-CD31 Antibody Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Anti-CD31 Antibody Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Anti-CD31 Antibody Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Anti-CD31 Antibody Sales (K Units), 2018-2023
Table 25. By Region - Global Anti-CD31 Antibody Sales (K Units), 2024-2029
Table 26. By Country - North America Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Anti-CD31 Antibody Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Anti-CD31 Antibody Sales, (K Units), 2018-2023
Table 29. By Country - North America Anti-CD31 Antibody Sales, (K Units), 2024-2029
Table 30. By Country - Europe Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Anti-CD31 Antibody Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Anti-CD31 Antibody Sales, (K Units), 2018-2023
Table 33. By Country - Europe Anti-CD31 Antibody Sales, (K Units), 2024-2029
Table 34. By Region - Asia Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Anti-CD31 Antibody Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Anti-CD31 Antibody Sales, (K Units), 2018-2023
Table 37. By Region - Asia Anti-CD31 Antibody Sales, (K Units), 2024-2029
Table 38. By Country - South America Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Anti-CD31 Antibody Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Anti-CD31 Antibody Sales, (K Units), 2018-2023
Table 41. By Country - South America Anti-CD31 Antibody Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Anti-CD31 Antibody Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Anti-CD31 Antibody Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Anti-CD31 Antibody Sales, (K Units), 2024-2029
Table 46. BosterBio Company Summary
Table 47. BosterBio Anti-CD31 Antibody Product Offerings
Table 48. BosterBio Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. BosterBio Key News & Latest Developments
Table 50. Bio-Rad Company Summary
Table 51. Bio-Rad Anti-CD31 Antibody Product Offerings
Table 52. Bio-Rad Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Bio-Rad Key News & Latest Developments
Table 54. BD Biosciences Company Summary
Table 55. BD Biosciences Anti-CD31 Antibody Product Offerings
Table 56. BD Biosciences Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. BD Biosciences Key News & Latest Developments
Table 58. Abcam Company Summary
Table 59. Abcam Anti-CD31 Antibody Product Offerings
Table 60. Abcam Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Abcam Key News & Latest Developments
Table 62. RayBiotech Company Summary
Table 63. RayBiotech Anti-CD31 Antibody Product Offerings
Table 64. RayBiotech Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. RayBiotech Key News & Latest Developments
Table 66. GeneTex Company Summary
Table 67. GeneTex Anti-CD31 Antibody Product Offerings
Table 68. GeneTex Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. GeneTex Key News & Latest Developments
Table 70. BioLegend Company Summary
Table 71. BioLegend Anti-CD31 Antibody Product Offerings
Table 72. BioLegend Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. BioLegend Key News & Latest Developments
Table 74. BMA Biomedicals Company Summary
Table 75. BMA Biomedicals Anti-CD31 Antibody Product Offerings
Table 76. BMA Biomedicals Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. BMA Biomedicals Key News & Latest Developments
Table 78. Bethyl Laboratories Company Summary
Table 79. Bethyl Laboratories Anti-CD31 Antibody Product Offerings
Table 80. Bethyl Laboratories Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Bethyl Laboratories Key News & Latest Developments
Table 82. SouthernBiotech Company Summary
Table 83. SouthernBiotech Anti-CD31 Antibody Product Offerings
Table 84. SouthernBiotech Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. SouthernBiotech Key News & Latest Developments
Table 86. Elabscience Biotechnology Inc Company Summary
Table 87. Elabscience Biotechnology Inc Anti-CD31 Antibody Product Offerings
Table 88. Elabscience Biotechnology Inc Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. Elabscience Biotechnology Inc Key News & Latest Developments
Table 90. Merck Company Summary
Table 91. Merck Anti-CD31 Antibody Product Offerings
Table 92. Merck Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. Merck Key News & Latest Developments
Table 94. Leica Biosystems Company Summary
Table 95. Leica Biosystems Anti-CD31 Antibody Product Offerings
Table 96. Leica Biosystems Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. Leica Biosystems Key News & Latest Developments
Table 98. Beijing Solarbio Science & Technology Company Summary
Table 99. Beijing Solarbio Science & Technology Anti-CD31 Antibody Product Offerings
Table 100. Beijing Solarbio Science & Technology Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 101. Beijing Solarbio Science & Technology Key News & Latest Developments
Table 102. Wuhan Fine Biotech Company Summary
Table 103. Wuhan Fine Biotech Anti-CD31 Antibody Product Offerings
Table 104. Wuhan Fine Biotech Anti-CD31 Antibody Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 105. Wuhan Fine Biotech Key News & Latest Developments
Table 106. Anti-CD31 Antibody Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 107. Global Anti-CD31 Antibody Capacity Market Share of Key Manufacturers, 2021-2023
Table 108. Global Anti-CD31 Antibody Production by Region, 2018-2023 (K Units)
Table 109. Global Anti-CD31 Antibody Production by Region, 2024-2029 (K Units)
Table 110. Anti-CD31 Antibody Market Opportunities & Trends in Global Market
Table 111. Anti-CD31 Antibody Market Drivers in Global Market
Table 112. Anti-CD31 Antibody Market Restraints in Global Market
Table 113. Anti-CD31 Antibody Raw Materials
Table 114. Anti-CD31 Antibody Raw Materials Suppliers in Global Market
Table 115. Typical Anti-CD31 Antibody Downstream
Table 116. Anti-CD31 Antibody Downstream Clients in Global Market
Table 117. Anti-CD31 Antibody Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Anti-CD31 Antibody Segment by Type in 2022
Figure 2. Anti-CD31 Antibody Segment by Application in 2022
Figure 3. Global Anti-CD31 Antibody Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Anti-CD31 Antibody Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Anti-CD31 Antibody Revenue, 2018-2029 (US$, Mn)
Figure 7. Anti-CD31 Antibody Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Anti-CD31 Antibody Revenue in 2022
Figure 9. By Type - Global Anti-CD31 Antibody Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Anti-CD31 Antibody Revenue Market Share, 2018-2029
Figure 11. By Type - Global Anti-CD31 Antibody Sales Market Share, 2018-2029
Figure 12. By Type - Global Anti-CD31 Antibody Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Anti-CD31 Antibody Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Anti-CD31 Antibody Revenue Market Share, 2018-2029
Figure 15. By Application - Global Anti-CD31 Antibody Sales Market Share, 2018-2029
Figure 16. By Application - Global Anti-CD31 Antibody Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Anti-CD31 Antibody Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Anti-CD31 Antibody Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Anti-CD31 Antibody Revenue Market Share, 2018-2029
Figure 20. By Region - Global Anti-CD31 Antibody Sales Market Share, 2018-2029
Figure 21. By Country - North America Anti-CD31 Antibody Revenue Market Share, 2018-2029
Figure 22. By Country - North America Anti-CD31 Antibody Sales Market Share, 2018-2029
Figure 23. US Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Anti-CD31 Antibody Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Anti-CD31 Antibody Sales Market Share, 2018-2029
Figure 28. Germany Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 29. France Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Anti-CD31 Antibody Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Anti-CD31 Antibody Sales Market Share, 2018-2029
Figure 37. China Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 41. India Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Anti-CD31 Antibody Revenue Market Share, 2018-2029
Figure 43. By Country - South America Anti-CD31 Antibody Sales Market Share, 2018-2029
Figure 44. Brazil Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Anti-CD31 Antibody Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Anti-CD31 Antibody Sales Market Share, 2018-2029
Figure 48. Turkey Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Anti-CD31 Antibody Revenue, (US$, Mn), 2018-2029
Figure 52. Global Anti-CD31 Antibody Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Anti-CD31 Antibody by Region, 2022 VS 2029
Figure 54. Anti-CD31 Antibody Industry Value Chain
Figure 55. Marketing Channels


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 抗CD3抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル
  • 抗B1抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル
  • 抗カスパーゼ3抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル
  • CD161抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル
  • ASL抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23DC12248 )"抗CD31抗体のグローバル市場展望 2023年-2029年：モノクローナル、ポリクローナル" (英文：Anti-CD31 Antibody Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。